Brief: Entero Therapeutics Announces Proposed Reverse Merger With Journey Therapeutics
13/11/2024 13:11
Nov 13 (Reuters) - Entero Therapeutics Inc ENTO.O :
* ENTERO THERAPEUTICS ANNOUNCES PROPOSED REVERSE MERGER WITH
JOURNEY THERAPEUTICS, A CLINICAL STAGE, FIRST-IN-CLASS,
NEXT-GENERATION ADC-RIVALLING NANO-IMMUNOCONJUGATES
BIOPHARMACEUTICAL COMPANY
* ENTERO THERAPEUTICS INC - JOURNEY SHAREHOLDERS TO ACQUIRE
99% OF
ENTERO EQUITY
* ENTERO THERAPEUTICS INC - COMBINED COMPANY TO OPERATE AS
JOURNEY
THERAPEUTICS AND APPLY FOR NASDAQ LISTING
Source text: urn:newsml:reuters.com:*:nGNX64clf6
Further company coverage: ENTO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GridAI Technologies
See all newsBrief: Gridai Technologies Corp - Enters $2.54 Million Private Placement Of Shares And Warrants - SEC Filing
Brief: IBN Announces Latest Episode Of The Techmediawire Podcast Featuring Marshall Chapin, CEO Of Grid Ai Corp.
Brief: Entero Therapeutics Terminated Interim CEO And Chairman Richard Joel Paolone Effective Immediately - SEC Filing
Brief: Entero Therapeutics Inc - Now Offering 15.2 Million Shares Of Common Stock
Brief: Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement